Dcspka, below is the quote from the study.
"DR-70 provided a sensitivity of 81.6% and a specificity of 77.1% for HCC."
The conclusion for the study states that DR-70 is equal to the performance of an AFP test.
If you look up the use of AFP for cancer, it states that it should only be used to monitoring HCC or to screen those cases where HCC is suspected. AFP is not a widely used test and it is mostly used in the Oreint as is also where DR-70 is mostly used.
You should look at the performance numbers for the test.
81.6 sensitivity. That means it misses 18.4% of the actual cancers that exist but it also has a whopping 22.9% of fales positives when given to people who have no cancer at all.
If you give the test to 1000 healthy people, it would state that 2290 of that 10,000 have cancer when they don't.
Now look at the actual rate of HCC in 10,000 people screened for actual seer statistics.
"Asian/Pacific Islander
2.14 per 10,000 men
.82 per 10,000 women"
Given the above data, if you screen 10,000 Asian men, you might be able to find just less than 2 actual cases but you would have 2,290 false positives.
That is a horrible test for screening
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.
